Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 59 3-Year Share Buyback Ratio is -4.20 as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 59/100 and a GF Value™ of $2.06 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,186 Biotechnology companies, Devonian Health Group ranks better than 68.72% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Devonian Health Group's current 3-Year Share Buyback Ratio was -4.20%.
The historical rank and industry rank for Devonian Health Group's 3-Year Share Buyback Ratio or its related term are showing as below:
DVHGF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -686.3 Med: -18.55 Max: 61.9
Current: -4.2
During the past 9 years, Devonian Health Group's highest 3-Year Share Buyback Ratio was 61.90%. The lowest was -686.30%. And the median was -18.55%.
DVHGF's 3-Year Share Buyback Ratio is ranked better than 68.72% of 1186
companies
in the Biotechnology industry
Industry Median: -11.6
vs DVHGF: -4.20
Devonian Health Group (OTCPK:DVHGF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Devonian Health Group 3-Year Share Buyback Ratio Related Terms
DVHGF vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Devonian Health Group's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's 3-Year Share Buyback Ratio falls into.
Devonian Health Group 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -4.20 mean?
Devonian Health Group (DVHGF) has a 3-Year Share Buyback Ratio of -4.20 as of Apr. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #371 out of 1186 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Devonian Health Group's 3-Year Share Buyback Ratio too high?
Devonian Health Group's current 3-Year Share Buyback Ratio is -4.20. Based on the distribution chart, Devonian Health Group ranks #371 out of 1186 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #371 out of 1186 companies for 3-Year Share Buyback Ratio. This puts Devonian Health Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Devonian Health Group and its competitors. Devonian Health Group's current 3-Year Share Buyback Ratio is -4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.06, compared to a current price of $5.88 — trading 185.2% above its estimated fair value. The current 3-Year Share Buyback Ratio is -4.20. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current 3-Year Share Buyback Ratio is -4.20 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $5.88 is trading 185.2% above its estimated GF Value™ of $2.06.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
3-Year Share Buyback Ratio: -4.20
GF Value™: $2.06 vs. price of $5.88 (185.2% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score
Get the complete analysis for DVHGF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
